Clinical Trial Update: Multiple Ascending Dose Study of GMC-252-L-Lys Salt in Healthy Subjects and Type 2 Diabetics [Phase 1]

View source ↗

Summary

Phase 1 multiple ascending dose study of GMC-252-L-Lys Salt in healthy subjects and Type 2 Diabetes Mellitus patients was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• GMC-252-L-Lys Salt (GMC-252-L-Lys Salt)

Snippet

Sponsor: Genmedica Therapeutics S.L. | Conditions: Healthy, Type 2 Diabetes Mellitus | Phase 1 | Status: TERMINATED